TAM
KALV

Tyers Asset Management’s KalVista Pharmaceuticals KALV Stock Holding History

Tyers Asset Management’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$12K Hold
1,064
– – ﹤0.01% 981
2019
Q2 		$24K Hold
1,064
– – ﹤0.01% 956
2019
Q1 		$31K Hold
1,064
– – ﹤0.01% 942
2018
Q4 		$21K Buy
+1,064
New +$21.4K ﹤0.01% 916

Other funds holding KALV

SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Tyers Asset Management's KALV Position: Q3 2019 in Review

Tyers Asset Management held its KalVista Pharmaceuticals (KALV) position steady in Q3 2019 at 1,064 shares worth $12K. The position accounts for ﹤0.01% of the portfolio, ranked #981.

Tyers Asset Management first reported a position in KALV in Q4 2018 and has held it in 4 quarters since. The position peaked at $31K in Q1 2019. 76 funds tracked by Wall St. Rank hold KALV as of Q3 2019.

  • Tyers Asset Management held 1,064 shares of KalVista Pharmaceuticals worth $12K as of Q3 2019.
  • Tyers Asset Management left its KalVista Pharmaceuticals share count unchanged in Q3 2019.
  • KalVista Pharmaceuticals made up ﹤0.01% of Tyers Asset Management's portfolio in Q3 2019, its #981 holding.
  • Tyers Asset Management first reported a position in KalVista Pharmaceuticals in Q4 2018 and has held it in 4 quarters since.
  • Tyers Asset Management's KalVista Pharmaceuticals position peaked at $31K in Q1 2019.
  • 76 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q3 2019.

Based on Tyers Asset Management's 13F filing for Q3 2019, filed 14 Nov 2019.